Interested parties should contact:
Mag. Johanna Uhlmann Head of Business Development
Marinomed Biotechnologie GmbH
Tel: +43 (0)1 25077 4460 email@example.com
Marinomed has a track record of success with one product already successfully marketed internationally and several follow-on compounds in development.
Marinomed is interested in talking to companies looking to in-license the anti-viral respiratory technology platform MAVIREX for the generation of innovative anti-viral products in such indications as the common cold or influenza.
The platform can be used to improve existing symptomatic therapies by adding anti-viral efficacy. It can therefore generate value by extending product lifecycles with new combination therapies and strengthen portfolios of marketed products and development candidates.
Marinomed’s first product, based on its anti-viral respiratory technology platform MAVIREX, is on the market as an anti-viral nasal spray for the prevention and treatment of common cold in several markets. The nasal spray addresses the cause of the common cold rather than just reducing the symptoms. Marketing rights for 54 countries were out-licensed to Boehringer Ingelheim in 2010. Further 19 countries were out-licensed to local partners all over the world.
Interested parties should contact Mag. Johanna Uhlmann, Head of Business Development, on +43 1 25077 4460.